Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759073 | 0.94 | TP53 (0.49) | PDE10ALMNAMAPTELANETP53 | |
| SCHEMBL5759479 | 0.94 | PDE10A (0.48) | PDE10AP2RX7ELANETP53CNR2 | |
| SCHEMBL5759317 | 0.94 | TP53 (0.52) | PDE10ALMNAMAPTELANETP53 | |
| SCHEMBL5758809 | 0.93 | PDE10A (0.45) | PDE10ALMNAMAPTP2RX7ELANE | |
| SCHEMBL27624377 | 0.92 | PDE10A (0.45) | PDE10ALMNAMAPTP2RX7ELANE | |
| SCHEMBL5758260 | 0.92 | PDE10A (0.46) | PDE10AP2RX7ELANEKLKB1KMT2A | |
| SCHEMBL5759410 | 0.92 | PDE10A (0.48) | PDE10ALMNAP2RX7ELANETP53 | |
| SCHEMBL5760593 | 0.91 | ELANE (0.55) | PDE10AELANE | |
| SCHEMBL5759228 | 0.91 | ELANE (0.53) | LMNAMAPTP2RX7ELANE | |
| SCHEMBL5758891 | 0.91 | PDE10A (0.50) | PDE10AP2RX7ELANEKLKB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | PDE10A 2816/4885LMNA 509/4885MAPT 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.